July 25th 2025
Study links early childhood eczema timing to risk of allergies like food allergy, asthma, and rhinitis, with five distinct disease phenotypes identified.
July 7th 2025
Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.
June 17th 2025
The federal agency has assigned a target action date of January 31, 2026, for a decision.
May 7th 2025
Prescriptions for the epinephrine nasal spray are now available for patients aged 4 years and up who weigh 33 to < 66 lbs.
April 24th 2025
The study involved 88 pediatric patients, with 12.5% showing positive intradermal test results and 1.1% positive subcutaneous provocation.